scholarly journals Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer

2020 ◽  
Author(s):  
Tanya E. Keenan ◽  
Tianyu Li ◽  
Tuulia Vallius ◽  
Jennifer L. Guerriero ◽  
Nabihah Tayob ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Efficacy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Molecular Response

scholarly journals Clinical efficacy of administering oxaliplatin combined with S-1 in the treatment of advanced triple-negative breast cancer

2015 ◽  
Vol 10 (1) ◽  
pp. 379-385 ◽  
Author(s):  
JUN LIU ◽  
YANG XIAO ◽  
WEI WEI ◽  
JIAN-XIONG GUO ◽  
YANG-CHEN LIU ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Efficacy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative

scholarly journals Molecular Investigation on a Triple Negative Breast Cancer Xenograft Model Exposed to Proton Beams

2020 ◽  
Vol 21 (17) ◽  
pp. 6337 ◽  
Author(s):  
Francesco P. Cammarata ◽  
Giusi I. Forte ◽  
Giuseppe Broggi ◽  
Valentina Bravatà ◽  
Luigi Minafra ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Xenograft Model ◽  
Molecular Response ◽  
Proton Beams ◽  
Therapeutic Choice ◽  
Inaccessible Area ◽  
Surrounding Healthy Tissue

Specific breast cancer (BC) subtypes are associated with bad prognoses due to the absence of successful treatment plans. The triple-negative breast cancer (TNBC) subtype, with estrogen (ER), progesterone (PR) and human epidermal growth factor-2 (HER2) negative receptor status, is a clinical challenge for oncologists, because of its aggressiveness and the absence of effective therapies. In addition, proton therapy (PT) represents an effective treatment against both inaccessible area located or conventional radiotherapy (RT)-resistant cancers, becoming a promising therapeutic choice for TNBC. Our study aimed to analyze the in vivo molecular response to PT and its efficacy in a MDA-MB-231 TNBC xenograft model. TNBC xenograft models were irradiated with 2, 6 and 9 Gy of PT. Gene expression profile (GEP) analyses and immunohistochemical assay (IHC) were performed to highlight specific pathways and key molecules involved in cell response to the radiation. GEP analysis revealed in depth the molecular response to PT, showing a considerable immune response, cell cycle and stem cell process regulation. Only the dose of 9 Gy shifted the balance toward pro-death signaling as a dose escalation which can be easily performed using proton beams, which permit targeting tumors while avoiding damage to the surrounding healthy tissue.

scholarly journals Clinical efficacy of local targeted chemotherapy for triple-negative breast cancer

2011 ◽  
Vol 45 (2) ◽  
Author(s):  
Jinsong He ◽  
Xianming Wang ◽  
Hong Guan ◽  
Weicai Chen ◽  
Ming Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Efficacy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Targeted Chemotherapy

Safety and initial clinical efficacy of a dendritic cell (DC) vaccine in locally advanced, triple-negative breast cancer (TNBC) patients (pts).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 1086-1086 ◽  
Author(s):  
Joyce O'Shaughnessy ◽  
Lee K Roberts ◽  
Jennifer L Smith ◽  
Maren K Levin ◽  
Roxana Timis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dendritic Cell ◽  
Clinical Efficacy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Locally Advanced ◽  
Dc Vaccine

Identification of new therapeutic leads for triple negative breast cancer subtypes

Planta Medica ◽  
2015 ◽  
Vol 81 (11) ◽  
Author(s):  
AJ Robles ◽  
L Du ◽  
S Cai ◽  
RH Cichewicz ◽  
SL Mooberry
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Breast Cancer Subtypes ◽  
Cancer Subtypes ◽  
Therapeutic Leads

Immediate and long-term results of the first line chemotherapy in patients with metastatic triple negative breast cancer. Final analysis of randomized study

2020 ◽  
pp. 75-80
Author(s):  
S.A. Lyalkin ◽  
◽  
L.A. Syvak ◽  
N.O. Verevkina ◽  
◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Randomized Study ◽  
Progression Free Survival ◽  
First Line ◽  
Free Survival ◽  
Group 2 ◽  
Line Chemotherapy ◽  
Group 1

The objective: was to evaluate the efficacy of the first line chemotherapy in patients with metastatic triple negative breast cancer (TNBC). Materials and methods. Open randomized study was performed including 122 patients with metastatic TNBC. The efficacy and safety of the first line chemotherapy of regimens АТ (n=59) – group 1, patients received doxorubicine 60 мг/м2 and paclitaxel 175 мг/м2 and ТР (n=63) – group 2, patients received paclitaxel 175 мг/м2 and carboplatin AUC 5 were evaluated. Results. The median duration of response was 9.5 months (4.5–13.25 months) in patients received AT regimen and 8.5 months (4.7–12.25 months), in TP regimen; no statistically significant differences were observed, р=0.836. The median progression free survival was 7 months (95% CI 5–26 months) in group 1 and 7.5 months (95% CI 6–35 months) in group 2, p=0.85. Both chemotherapy regimens (AT and TP) had mild or moderate toxicity profiles (grade 1 or 2 in most patients). No significant difference in gastrointestinal toxicity was observed. The incidence of grade 3–4 neutropenia was higher in patients of group 2 (TP regimen): 42.8% versus 27% (р<0.05). Conclusions. Both regimens of chemotherapy (AT and TP) are appropriate to use in the first line setting in patients with metastatic TNBC. Key words: metastatic triple negative breast cancer, chemotherapy, progression free survival, chemotherapy toxicity.

Sign in / Sign up

Export Citation Format

Share Document